Literature DB >> 1933807

Expression of class I histocompatibility antigens in transitional cell carcinoma of the urinary bladder in relation to survival.

I Levin1, T Klein, J Goldstein, O Kuperman, J Kanetti, B Klein.   

Abstract

The expression of class I histocompatibility antigens (HLA) in transitional cell carcinoma of the bladder was studied by the immunoperoxidase technique and correlated with tumor differentiation and survival. Tumors of 33 patients who underwent cystectomy were examined; 57% of the tumors expressed HLA class I antigens. Positive expression was observed in 5 of 6 cases with Grade 1 tumors, 8 of 13 with Grade 2, and 6 of 14 with Grade 3. The 5-year survival was significantly better in patients with HLA class I-positive tumors (74%) compared with those with negative tumors (36%, P less than 0.05). The expression of HLA class I on tumor cells may serve as a target for the immune response and control the metastatic potential of the tumor. These results suggest that HLA class I expression in bladder carcinoma is a prognostic indicator that should be considered in treatment planning.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1933807     DOI: 10.1002/1097-0142(19911215)68:12<2591::aid-cncr2820681212>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer.

Authors:  Vid Leko; Lucas A McDuffie; Zhili Zheng; Jared J Gartner; Todd D Prickett; Andrea B Apolo; Piyush K Agarwal; Steven A Rosenberg; Yong-Chen Lu
Journal:  J Immunol       Date:  2019-04-29       Impact factor: 5.422

2.  LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas.

Authors:  Isabel Maleno; Jose Maria Romero; Teresa Cabrera; Laura Paco; Natalia Aptsiauri; Jose Manuel Cozar; Miguel Tallada; Miguel Angel López-Nevot; Federico Garrido
Journal:  Immunogenetics       Date:  2006-05-17       Impact factor: 2.846

3.  Immunocytochemical demonstration of down regulation of HLA class-I molecule expression in human metastatic breast carcinoma.

Authors:  Masanao Saio; Matt Teicher; Gaynor Campbell; Helen Feiner; Yara Delgado; Alan B Frey
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

Review 4.  Evolving immunotherapeutic strategies in bladder and renal cancer.

Authors:  T R L Griffiths; J K Mellon
Journal:  Postgrad Med J       Date:  2004-06       Impact factor: 2.401

Review 5.  The immunoregulatory mechanisms of carcinoma for its survival and development.

Authors:  Caigan Du; Yuzhuo Wang
Journal:  J Exp Clin Cancer Res       Date:  2011-01-21

6.  Clinical implication of HLA class I expression in breast cancer.

Authors:  Koichi Kaneko; Sumiya Ishigami; Yuko Kijima; Yawara Funasako; Munetsugu Hirata; Hiroshi Okumura; Hiroyuki Shinchi; Chihaya Koriyama; Shinichi Ueno; Heiji Yoshinaka; Shoji Natsugoe
Journal:  BMC Cancer       Date:  2011-10-20       Impact factor: 4.430

7.  Understanding heterogeneous tumor microenvironment in metastatic melanoma.

Authors:  Yiyi Yan; Alexey A Leontovich; Michael J Gerdes; Keyur Desai; Jinhong Dong; Anup Sood; Alberto Santamaria-Pang; Aaron S Mansfield; Chrystal Chadwick; Rong Zhang; Wendy K Nevala; Thomas J Flotte; Fiona Ginty; Svetomir N Markovic
Journal:  PLoS One       Date:  2019-06-05       Impact factor: 3.240

Review 8.  Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.

Authors:  Karthik Dhatchinamoorthy; Jeff D Colbert; Kenneth L Rock
Journal:  Front Immunol       Date:  2021-03-09       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.